426
Views
19
CrossRef citations to date
0
Altmetric
Research Articles

In silico approach of naringin as potent phosphatase and tensin homolog (PTEN) protein agonist against prostate cancer

, , , , , , , , & show all
Pages 1629-1638 | Received 06 Feb 2020, Accepted 27 Sep 2020, Published online: 09 Oct 2020
 

Abstract

Prostate cancer (PC) is one of the major impediments affecting men, which leads approximately 31,620 deaths in both developing and developed countries. Although some chemotherapy drugs have been reported for prostate cancer, they are not effective due to the lack of safety, efficacy and low selectivity. Hence, the novel alternative anticancer agents with remarkable effect are highly appreciable. Natural plants contain several bio-active compounds which have been traditionally used for the various medical treatments. Particularly, naringin is a natural bio-active compound commonly found in the citrus fruits, which have shown numerous biological activities. Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, which activates both lipid phosphates and protein phosphates. The PTEN gene is negative regulator of PI3K/AKT/mTOR pathways, since, this signaling pathway play an essential role in the cell survival, proliferation and migration. In the present in silico investigation, structure based virtual screening, molecular docking, molecular dynamics simulation and Adsorption, Distribution, Metabolism, Excretion (ADME) prediction were employed to determine the binding affinity, stability and drug likeness properties of top ranked screened compounds and naringin, respectively. The results revealed that the complex has good molecular interactions, binding stability (peak between 0.3 and 0.4 nm) and no violations in the Lipinski Rule of 5 in naringin, but the screened compounds violated the drug likeness properties. From the in silico analyses, it is identified that naringin compound might assist in the development of novel therapeutic candidate against prostate cancer.

Communicated by Ramaswamy H. Sarma

Disclosure statement

There are no conflicts to declare.

Additional information

Funding

The authors thankfully acknowledge the UGC-Innovative [No.F. 14-13/2013 (Inno/ASIST)], DST-FIST [SR/FST/LSI-667/2016(C)], DST PURSE [SR/PURSE Phase 2/38 (G)], MHRD-RUSA 2.0 [F.24/51/2014-U Policy (TNMulti-Gen), Dept. of Edn. Govt. of India] and DST-SERB [EEQ/2016/000044] for the financial supports and infrastructure facilities.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.